Swiss National Bank Has $139.60 Million Stake in Vertex Pharmaceuticals Incorporated (VRTX)

0

Swiss National Bank grew its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 918,209 shares of the pharmaceutical company’s stock after buying an additional 11,100 shares during the quarter. Swiss National Bank owned 363,071.97% of Vertex Pharmaceuticals worth $139,604,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the company. BlackRock Inc. grew its holdings in shares of Vertex Pharmaceuticals by 0.8% during the second quarter. BlackRock Inc. now owns 19,405,981 shares of the pharmaceutical company’s stock valued at $2,500,849,000 after buying an additional 159,601 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Vertex Pharmaceuticals by 3.1% during the second quarter. Vanguard Group Inc. now owns 16,979,872 shares of the pharmaceutical company’s stock valued at $2,188,196,000 after buying an additional 504,982 shares during the last quarter. Jennison Associates LLC grew its holdings in shares of Vertex Pharmaceuticals by 253.8% during the second quarter. Jennison Associates LLC now owns 5,055,122 shares of the pharmaceutical company’s stock valued at $651,454,000 after buying an additional 3,626,368 shares during the last quarter. TIAA CREF Investment Management LLC grew its holdings in shares of Vertex Pharmaceuticals by 28.1% during the second quarter. TIAA CREF Investment Management LLC now owns 2,077,303 shares of the pharmaceutical company’s stock valued at $267,702,000 after buying an additional 456,290 shares during the last quarter. Finally, Wells Fargo & Company MN grew its holdings in shares of Vertex Pharmaceuticals by 4.5% during the second quarter. Wells Fargo & Company MN now owns 1,916,227 shares of the pharmaceutical company’s stock valued at $246,944,000 after buying an additional 83,314 shares during the last quarter. Hedge funds and other institutional investors own 93.06% of the company’s stock.

In other Vertex Pharmaceuticals news, COO Ian F. Smith sold 2,155 shares of the business’s stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $150.00, for a total value of $323,250.00. Following the completion of the transaction, the chief operating officer now owns 43,043 shares of the company’s stock, valued at approximately $6,456,450. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP David Altshuler sold 1,796 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $160.00, for a total transaction of $287,360.00. Following the completion of the transaction, the executive vice president now directly owns 107,807 shares of the company’s stock, valued at approximately $17,249,120. The disclosure for this sale can be found here. Insiders have sold a total of 220,094 shares of company stock worth $32,074,719 in the last ninety days. 1.80% of the stock is currently owned by insiders.

Several research analysts recently weighed in on the stock. Royal Bank Of Canada restated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Friday, October 27th. Needham & Company LLC restated a “buy” rating and set a $195.00 price target on shares of Vertex Pharmaceuticals in a report on Friday, October 27th. Robert W. Baird restated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Friday, October 27th. HC Wainwright restated a “hold” rating and set a $85.00 price target on shares of Vertex Pharmaceuticals in a report on Thursday, October 26th. Finally, Maxim Group restated a “buy” rating and set a $195.00 price target on shares of Vertex Pharmaceuticals in a report on Thursday, October 26th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-three have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $173.15.

“Swiss National Bank Has $139.60 Million Stake in Vertex Pharmaceuticals Incorporated (VRTX)” was GBand is owned by of DT GB gearsofbiz If you are viewing this and of United States & and law. The original version of this at http://gearsofbiz.com/2017/11/10/swiss-national-bank-has-139-60-million-stake-in-vertex-pharmaceuticals-incorporated-vrtx

Vertex Pharmaceuticals Incorporated (VRTX) traded down $1.19 during trading on Friday, reaching $146.98. 56,676 shares of the company were exchanged, compared to its average volume of 1,825,265. The company has a quick ratio of 3.14, a current ratio of 3.28 and a debt-to-equity ratio of 0.01. The company has a market cap of $37,277.87, a price-to-earnings ratio of 245.67, a PEG ratio of 3.74 and a beta of 1.63. Vertex Pharmaceuticals Incorporated has a twelve month low of $71.46 and a twelve month high of $167.85.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.49. The business had revenue of $578.20 million for the quarter, compared to analyst estimates of $522.07 million. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. Vertex Pharmaceuticals’s revenue was up 39.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.16 EPS. research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 0.72 earnings per share for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)




Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com’s FREE daily email newsletter.

Share.

Leave A Reply